ABSTRACT
A series of macrocyclic calcitonin gene-related peptide (CGRP) receptor antagonists identified using structure-based design principles, exemplified by HTL0028016 (1) and HTL0028125 (2), is described. Structural characterization by X-ray crystallography of the interaction of two of the macrocycle antagonists with the CGRP receptor ectodomain is described, along with structure-activity relationships associated with point changes to the macrocyclic antagonists. The identification of non-peptidic/natural product-derived, macrocyclic ligands for a G protein coupled receptor (GPCR) is noteworthy.
Subject(s)
Receptors, Calcitonin Gene-Related Peptide , Receptors, G-Protein-Coupled , Calcitonin Receptor-Like Protein/chemistry , Calcitonin Receptor-Like Protein/metabolism , Crystallography, X-Ray , Ligands , Receptors, Calcitonin Gene-Related Peptide/chemistry , Receptors, Calcitonin Gene-Related Peptide/metabolism , Receptors, G-Protein-Coupled/metabolismABSTRACT
Malaria remains the most prevalent tropical disease, and due to the spread of resistant parasites novel therapeutics are urgently needed. Azithromycin has shown potential in malaria treatment so we designed hybrid azalide molecules with the aim to improve activity against and selectivity for the malaria parasite. Novel hybrid molecules comprising 4-aminoquinoline moiety covalently liked to 15-membered azalide scaffold at position C-3' were synthesized and biologically evaluated. Antimalarial testing against Plasmodium falciparum sensitive and resistant strains confirmed the improved in vitro activity over azithromycin and chloroquine. Selectivity of the compounds (HepG2 IC(50)/P. falciparum IC(50) ratio) for the parasite was high (100-2700) and their antibacterial activity diminished. Even though oral bioavailability determined for compound 12 was low, novel quinoline C-3'-substituted 15-membered azalides represent an interesting subclass of antimalarial macrolides that need further research and evaluation.
Subject(s)
Aminoquinolines/chemistry , Aminoquinolines/pharmacology , Antimalarials/chemistry , Antimalarials/pharmacology , Macrolides/chemistry , Macrolides/pharmacology , Plasmodium falciparum/drug effects , Aminoquinolines/chemical synthesis , Antimalarials/chemical synthesis , Azithromycin/pharmacology , Cell Line , Chloroquine/pharmacology , Humans , Macrolides/chemical synthesis , Malaria/drug therapyABSTRACT
Novel classes of antimalarial drugs are needed due to emerging drug resistance. Azithromycin, the first macrolide investigated for malaria treatment and prophylaxis, failed as a single agent and thus novel analogues were envisaged as the next generation with improved activity. We synthesized 42 new 9a-N substituted 15-membered azalides with amide and amine functionalities via simple and inexpensive chemical procedures using easily available building blocks. These compounds exhibited marked advances over azithromycin in vitro in terms of potency against Plasmodium falciparum (over 100-fold) and high selectivity for the parasite and were characterized by moderate oral bioavailability in vivo. Two amines and one amide derivative showed improved in vivo potency in comparison to azithromycin when tested in a mouse efficacy model. Results obtained for compound 6u, including improved in vitro potency, good pharmacokinetic parameters, and in vivo efficacy higher than azithromycin and comparable to chloroquine, warrant its further development for malaria treatment and prophylaxis.
Subject(s)
Aminoquinolines/chemical synthesis , Antimalarials/chemical synthesis , Erythromycin/analogs & derivatives , Macrolides/chemical synthesis , Amides/chemical synthesis , Amides/pharmacokinetics , Amides/pharmacology , Amines/chemical synthesis , Amines/pharmacokinetics , Amines/pharmacology , Aminoquinolines/pharmacokinetics , Aminoquinolines/pharmacology , Animals , Antimalarials/pharmacokinetics , Antimalarials/pharmacology , Azithromycin/pharmacology , Cell Line, Tumor , Drug Resistance , Erythromycin/chemical synthesis , Erythromycin/pharmacokinetics , Erythromycin/pharmacology , Humans , Macrolides/pharmacokinetics , Macrolides/pharmacology , Malaria/drug therapy , Male , Mice , Microsomes, Liver/metabolism , Parasitic Sensitivity Tests , Plasmodium berghei , Plasmodium falciparum/drug effects , Rats , Structure-Activity RelationshipABSTRACT
Azithromycin, a first member of the azalide family of macrolides, while having substantial antimalarial activity, failed as a single agent for malaria prophylaxis. In this paper we present the first analogue campaign to identify more potent compounds from this class. Ureas and thioureas of 15-membered azalides, N''-substituted 9a-(N'-carbamoyl-ß-aminoethyl), 9a-(N'-thiocarbamoyl-ß-aminoethyl), 9a-[N'-(ß-cyanoethyl)-N'-(carbamoyl-ß-aminoethyl)], 9a-[N'-(ß-cyanoethyl)-N'-(thiocarbamoyl-ß-aminoethyl)], 9a-{N'-[ß-(ethoxycarbonyl)ethyl]-N'(carbamoyl-ß-aminoethyl)}, and 9a-[N'-(ß-amidoethyl)-N'-(carbamoyl-ß-aminoethyl)] of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A, were synthesized and their biological properties evaluated. The results obtained indicate a substantial improvement of the in vitro activity against P. falciparum (up to 88 times over azithromycin), particularly for compounds containing both sugars on the macrocyclic ring and aromatic moiety on 9a-position. The improved in vitro activity was not confirmed in the mouse model, likely due to an increase in lipophilicity of these analogues leading to a higher volume of distribution. Overall, with increased in vitro activity, promising PK properties, and modest in vivo efficacy, this series of molecules represents a good starting platform for the design of novel antimalarial azalides.